Codon Y791F mutations in a large kindred: Is prophylactic thyroidectomy always indicated?

World Journal of Surgery

Volumn 31, Issue 5, 2007, Pages 996-1001

  Vestergaard, Peter ^a   Vestergaard, Else Marie ^a   Brockstedt, Helle ^a   Christiansen, Peer ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; PENTAGASTRIN; PROTEIN RET;

ADOLESCENT; ADULT; AGED; ANALYZER; ARTICLE; CALCITONIN BLOOD LEVEL; CODON; CONFIDENCE INTERVAL; EXON; FAMILY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GOITER; HETEROZYGOTE; HUMAN; MALE; MUTATIONAL ANALYSIS; PENETRANCE; POLYMERASE CHAIN REACTION; PROTO ONCOGENE; RISK ASSESSMENT; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CODON; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; PEDIGREE; PENETRANCE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-RET; STATISTICS, NONPARAMETRIC; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 34248190842     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-006-0446-1     Document Type: Article

References (22)

1. Gertner ME, Kebebew E. Multiple endocrine neoplasia type 2. Curr Treat Options Oncol 2004;5:315-325.
2. Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET protooncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005;15:531-544.
3. Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003;138:409-416.
4. Leboulleux S, Baudin E, Travagli JP, et al. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004;61:299-310.
5. Menacho IP, Koster R, van der Sloot AM, et al. RET-Familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 2005;65:1729-1737.
6. Berndt I, Reuter M, Saller B, et al. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998;83:770-774.
7. Vierhapper H, Bieglmayer C, Heinze G, et al. Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin. Thyroid 2004;14:580-583.
8. Brauckhoff M, Gimm O, Hinze R, et al. Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation. Thyroid 2002;12:557-561.
9. Brauer VF, Scholz GH, Neumann S, et al. RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed?. Endocr Pract 2004;10:5-9.
10. Colombo-Benkmann M, Bramswig J, Hoppner W, et al. Surgical strategy in a kindred with a rare RET protooncogene mutation of variable penetrance with regard to multiple endocrine neoplasia. World J Surg 2002;26:1286-1290.
11. Fitze G, Schierz M, Bredow J, et al. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann Surg 2002;236:570-575.
12. Frank-Raue K, Heimbach C, Rondot S, et al. Hereditary medullary thyroid carcinoma-genotype-phenotype characterization. Dtsch Med Wochenschr 2003;128:1998-2002.
13. Gimm O, Niederle BE, Weber T, et al. RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia type 2A syndrome?. Surgery 2002;132:952-959.
14. Gimm O, Ukkat J, Niederle BE, et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 2004;28:1312-1316.
15. Babson AL, Olson DR, Palmieri T, et al. The IMMULITE assay tube: a new approach to heterogeneous ligand assay. Clin Chem 1991;37:1521-1522.
16. Calmettes C, Ponder BA, Fischer JA, et al. Early diagnosis of the multiple endocrine neoplasia type 2 syndrome: consensus statement. European community concerted action: medullary thyroid carcinoma. Eur J Clin Invest 1992;22:755-760.
17. Wells SA Jr, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237-247.
18. Kambouris M, Jackson CE, Feldman GL.. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations. Hum Mutat 1996;8:64-70.
19. Wiench M, Wygoda Z, Gubala E, et al. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 2001;19:1374-1380.
20. Pasini A, Geneste O, Legrand P, et al. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 1997;15:393-402.
21. Laurberg P, Pedersen KM, Hreidarsson A, et al. Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. J Clin Endocrinol Metab 1998;83:765-769.
22. Pedersen KM, Iversen E, Laurberg P. Urinary iodine excretion and individual iodine supplementation among elderly subjects: a cross-sectional investigation in the commune of Randers, Denmark. Eur J Endocrinol 1995;132:171-174.